Lisata shares are trading higher after the company announced it is pursuing damages through litigation over Kuva’s breached merger agreement, reviewing strategic alternatives, and cutting costs with a major workforce reduction to preserve cash.

Lisata Therapeutics Announces Suit Against Kuva Labs Seeking Damages And $2M Termination Fee; Cuts Approximately 72% Of Full-Time Employees

Lisata has filed suit in the Delaware Court of Chancery against Kuva over Kuva’s breach of the previously-disclosed Agreement and Plan of Merger dated March 6, 2026 (as amended, the "Merger Agreement"), seeking,

Lisata Therapeutics shares are trading lower after the company announced it has terminated its merger agreement with Kuva Labs.

Lisata Therapeutics Terminates Merger Agreement With Kuva Labs; Termination Due To Kuva Labs' Failure To Obtain Financing, Accept Tendered Shares; Board To Carry Out Strategic Options Including Asset Sale

https://www.sec.gov/ix?doc=/Archives/edgar/data/320017/000114036126029541/ef20078724_8k.htm